cisplatin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

596 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
R000007955: Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Completed
3
Japan
pemetrexed - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Shizuoka Cancer Center, AMED
Completely resected non-squamous non-small cell lung cancer patients (pathologic stage II-IIIA)
 
 
2017-004936-13: randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Essai randomisé évaluant l’ajout de nivolumab à l’association cisplatine-radiothérapie pour le traitement des cancers de la tête et du cou

Not yet recruiting
3
680
Europe
cisplatine, Infusion, Solution for infusion, OPDIVO, CISPLATINE HOSPIRA
GORTEC, GORTEC, BMS Group
Squamous cell carcinoma treated by primary surgeryStage III, stage IV (American Joint Committee on Cancer 7th edition)Oral cavity, oropharynx, hypopharynx or larynx Carcinome épidermoïde traité par chirurgieStade III, stade IV (American Joint Committee on Cancer 7th edition)Cavité orale, oropharynx, hypopharynx ou larynx, Locally advanced and post-operative squamous cell carcinoma of the head and neck Carcinome épidermoïde localement avancé et opéré de la tête et du cou, Diseases [C] - Cancer [C04]
 
 
2019-002463-10: A study of BLU-667 in patients with lung cancer

Not yet recruiting
3
250
Europe
Pralsetinib, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Pemetrexed, BLU-667, N/A, Capsule, Concentrate for solution for infusion, Powder for solution for infusion, Lyophilisate for solution for infusion, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Alimta
Blueprint Medicines Corporation, F. Hoffmann-La Roche Ltd, F. Hoffmann La-Roche Ltd, BLUEPRINT MEDICINES CORPORATION, Blueprint Medicines, F.Hoffmann-La Roche Ltd., F. Hoffmann La-Roche Ltd, F. Hoffmann-La Roche Ltd.
RET fusion-positive, Metastatic Non-Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT02879513: Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Recruiting
3
290
RoW
Paclitaxel, Taxol, Cisplatin, Epirubicin, Cyclophosphamide, 5-fluoruracil, 5-FU
RenJi Hospital
Invasive Ductal Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Inflammatory Breast Cancer
06/20
12/22
NCT00980460: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Active, not recruiting
3
236
Canada, Japan, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Dexrazoxane, 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), ADR-529, ICRF-187, Razoxane (+)-form, Soluble ICRF (L-isomer), Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Laboratory Biomarker Analysis, Liver Transplantation, Hepatic Transplantation, Liver Grafting, Liver Transplant, Transplantation of Liver, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
06/20
03/25
NCT03992885: Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Recruiting
3
70
RoW
Icotinib, Pemetrexed, platinum
Tianjin Medical University Cancer Institute and Hospital
Non-squamous Non-small Cell Lung Cancer
07/20
08/25
KEYNOTE-590, NCT03189719 / 2017-000958-19: First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/)

Completed
3
749
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Placebo, Cisplatin, 5-FU
Merck Sharp & Dohme LLC
Esophageal Neoplasms
07/20
07/23
2017-003832-35: Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial of the AIO /CAOGI /ACO

Not yet recruiting
3
200
Europe
Docetaxel, Oxaliplatin, 5-fluorouracil, Leucovorin, Cisplatin, Concentrate for solution for infusion, Solution for injection
Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest, Deutsche Krebshilfe
locally advanced resectable diffuse type adenocarcinoma of the oesophagogastric junction or the stomach, locally advanced resectable diffuse type gastric cancer, Diseases [C] - Cancer [C04]
 
 
2020-002626-86: A trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patients Etude comparant l’association chimiothérapie à base de sels de platine et pembrolizumab au pembrolizumab en monothérapie, en première ligne de traitement de cancers broncho-pulmonaires non à petites cellules (CBPNC)

Not yet recruiting
3
292
Europe
Pemrolizumab, carboplatine, cisplatine, paclitaxel, Pemetrexed, Powder and solvent for solution for injection, Solution for infusion, Solution for solution for injection, Solution for injection, KEYTRUDA, carboplatine, Cisplatine, paclitaxel, Pemetrexed
CHRU de Brest, CHRU de Brest
First line, stage IV non small-cell lung cancer (NSCLC) with PD L1 expression on ≥50 % of tumor cells Cancer bronchique non à petites cellules, Neoplasms benign, malignant and unspecified Oncologie médicale, Diseases [C] - Cancer [C04]
 
 
ChiCTR1900022288: Induction chemotherapy with GP versus TPF in III-IVA nasopharyngeal carcinoma: a randomized controlled trial

Not yet recruiting
3
378
 
gemcitabine + cisplatin ;docetaxel + cisplatin + fluorouracil
West China Hospital, Sichuan University; West China Hospital, Sichuan University, West China Hospital, Sichuan University
nasopharyngeal carcinoma
 
 
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/24
NACOPRAD, NCT02422563: NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB

Not yet recruiting
3
534
Europe
hysterectomy, Radiation, Cisplatin, Paclitaxel, Carboplatin, Ifosfamide
Charite University, Berlin, Germany
Cervical Cancer
10/20
10/25
2016-001816-39: Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Comparaison de deux schémas de traitement pour les tumeurs des sinus et des glandes salivaires: chimio-radiothérapie versus radiothérapie.

Not yet recruiting
3
342
Europe
Cisplatine, Solution for infusion, Cisplatine hospira
GORTEC, GORTEC
- Tumeurs réséquées des sinus ou des glandes salivaires T3-4, N0 ou T1-4, N1-3 ou T1-2 N0, avec berges envahies ou marges positives - Tumeurs non résécables ou non opérables des sinus ou des glandes salivaires- Carcinomes des glandes salivaires principales - Tumeurs malignes des sinus, - Tumeurs réséquées des sinus ou des glandes salivaires - Tumeurs non opérables des sinus ou des glandes salivaires- Carcinomes des glandes salivaires principales - Tumeurs malignes des sinus, Diseases [C] - Cancer [C04]
 
 
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Checkmark From trial for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial for NSCLC at ESMO 2020
Checkmark From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Checkmark From trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC
More
Completed
3
334
RoW
Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed, Cisplatin or Carboplatin,Pemetrexed
BeiGene
Non-Small Cell Lung Cancer
10/20
04/23
NCT02001168: Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Active, not recruiting
3
392
RoW
Pemetrexed, Alimta, Docetaxel, Taxotere, rh-Endostatin, Endostar, Cis-platinum, Platinol
Xinjiang Medical University
Non-small Cell Lung Cancer
12/20
10/22
NCT02461043: Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma

Recruiting
3
386
RoW
paclitaxel; cisplatin, radiation
Chinese Academy of Medical Sciences
Esophageal Cancer
12/20
12/23
INDUCTION, NCT03815903: Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
3
434
RoW
Induction chemotherapy, Chemoradiotherapy
Barretos Cancer Hospital
Locally Advanced Malignant Neoplasm
12/20
12/25
ARIEL4, NCT02855944 / 2016-000816-14: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Checkmark Data from ARIEL4 trial for BRCA1/2-mutated ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from ARIEL4 trial for BRCA1/2-mutated ovarian cancer at ESMO 2022
Checkmark Subgroup analysis data from ARIEL4 trial for ovarian cancer at ASCO 2021
Jun 2021 - Jun 2021: Subgroup analysis data from ARIEL4 trial for ovarian cancer at ASCO 2021
Checkmark Data from ARIEL4 trial for advanced ovarian cancer
More
Completed
3
349
Europe, Canada, US, RoW
Chemotherapy, Cisplatin, carboplatin, carboplatin/paclitaxel, carboplatin/gemcitabine, paclitaxel, Rucaparib, CO-338, AG 14699, PF 01367338, Rubraca
zr Pharma & GmbH, Foundation Medicine
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
12/20
09/22
ChiCTR-TRC-12001979: The prospective,multicenter, randomized clinical trial to compare weekly cisplatin CCRT and every three weeks cisplatin CCRT in advanced nasopharyngeal carcinoma

Completed
3
520
 
cisplatin CCRT every three weeks ;cisplatin CCRT every week
Nasopharyngeal Carcinoma Department of Sun Yat-sen University Cancer Center; Nasopharyngeal Carcinoma Department of Sun Yat-sen University Cancer Center, Self-financing
Nasopharyngeal Carcinoma
 
 
TOPIC-NEC, UMIN000014795: Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,)

Active, not recruiting
3
170
Japan
etoposide IV - Generic mfg., cisplatin - Generic mfg., irinotecan - Generic mfg.
Japan Clinical Oncology Group (JCOG), Japan Agency for Medical Research and Development
Unresecectable or recurrent neuroendocrine carcinoma.
 
 
ChiCTR1900020790: A randomized, multicenter, phase III trial for apatinib combined with 5-fluorouracil (5-fu) and cisplatin versus 5-fluorouracil and cisplatin for the treatment of recurrent or metastatic nasopharyngeal carcinoma

Recruiting
3
300
 
dosage regime:PF+Apatinib ;PF protocol
the First Affiliated Hospital of Guangxi Medical University; None, Provided by the first affiliated hospital of guangxi medical university
recurrent or metastatic nasopharyngeal carcinoma
 
 
CheckMate 648, NCT03143153 / 2016-001514-20: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Checkmark Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Checkmark Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for 1L ESCC based on Checkmate-648 trial
May 2022 - May 2022: Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for 1L ESCC based on Checkmate-648 trial
Checkmark Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
More
Active, not recruiting
3
970
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558 (Nivolumab), Opdivo (Nivolumab), Ipilimumab, BMS-734016 (Ipilimumab), Yervoy (Ipilimumab), Cisplatin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Various Advanced Cancer
01/21
01/25
ChiCTR1900021887: A Randomized, Open, Controlled Phase III Observation of Curative Effect Clinical Study On Locally Advanced Beast Cancer Patients who Switch to GP Regimen NC After Receiving Poor Effect from TAC Regimen NC

Not yet recruiting
3
300
 
Cisplatin plus gemcitabine ;Vinorelbine bitartrate plus Cisplatin ;TAC
Affliated Tumor Hospital of Xinjiang Medical University; Affliated Tumor Hospital of Xinjiang Medical University, Self-pay
Locally advanced breast cancer
 
 
NCT01004978: Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed
3
235
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mitomycin, Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Pharmacological Study, Placebo Administration, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
National Cancer Institute (NCI)
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
02/21
12/22
ChiCTR1800015063: A randomized, parallel and multicenter study of the intervention effects of three chemotherapy regimens in patients with first-line metastatic esophageal squamous cell carcinoma

Recruiting
3
1308
 
cisplatin plus 5- fluorouracil ;paclitaxel plus cisplatin ;paclitaxel plus nedaplatin
Nanyang Central Hospital, Henan; Nanyang Central Hospital, Henan, raise independently
metastatic esophageal squamous cell carcinoma
 
 
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Checkmark Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Checkmark Full data presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2021
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
12/26
Jupiter06, NCT03829969: Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Checkmark Data from JUPITER-06 trial in esophageal squamous cell cancer
Mar 2022 - Mar 2022: Data from JUPITER-06 trial in esophageal squamous cell cancer
Checkmark Data from JUPITER-06 trial for advanced or metastatic esophageal squamous cell cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from JUPITER-06 trial for advanced or metastatic esophageal squamous cell cancer at ESMO 2021
Checkmark Data from JUPITER-06 for in combination with paclitaxel/cisplatin for the treatment in patients with advanced in 1L ESCC
More
Completed
3
514
RoW
Toripalimab, JS001, TAB001
Shanghai Junshi Bioscience Co., Ltd.
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
03/21
09/23
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Checkmark Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Jun 2022 - Jun 2022: Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Checkmark Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Jun 2022 - Jun 2022: Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Checkmark Presentation of data from RATIONALE 309 trial for 1L recurrent or metastatic nasopharyngeal cancer at ASCO plenary series 2022
More
Active, not recruiting
3
256
RoW
Tislelizumab, BGB-A317, Placebo, Gemcitabin, Cisplatin
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
03/21
06/25
2020-001001-22: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, unresctable ESCC

Not yet recruiting
3
600
Europe
Durvalumab, Cisplatin, capecitabine, 5-fluorouracil, MEDI4736, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Cisplatin NeoCorp® 1 mg/mL - concentrate for solution for infusion, Capecitabine (Capecitabin cell pharm® 150 mg and 500 mg film-coated tablets), 5-FU medac 50 mg/ml, solution for injection, Capecitabine Accord 150 mg and 500 mg film coated tablets, Cisplatin Teva® 1 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Benda-5 FU 50 mg/ml, solution for injection
AstraZeneca AB, AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Specific type of Esophageal cancer called "Esophageal Squamous Cell Carcinoma" (ESCC) that cannot be removed by surgery, Diseases [C] - Cancer [C04]
 
 
ChiCTR-TRC-13003285: A Multicenter Phase III Trial of Induction Chemotherapy with 5-Fu and Loboplatin versus Cisplatin followed by Concurrent Chemoradiotherapy With Loboplatin versus Cisplatin and IMRT in Locally Advanced Nasopharyngeal Carcinoma

Completed
3
492
 
1. Induction chemotherapy with Loboplatin and 5-FU (LF)(3 weekly), LBP 30mg/m2 d1; d22, 5-Fu 4g/m2 120hciv, d1-5; d22-26; 2. Concurrent chemoradiotherapy with Loboplatin and IMRT, LBP 30mg/m2, d43; d64; 3. Radical radiotherapy: after two periods of induction chemotherapy of LF. PTVnx: 68-70Gy/30-32f PTVnd: 62-68Gy/30-32f PTV1: 60-64Gy/30-32f PTV2: 54-58Gy/30-32f ;1. Induction chemotherapy with cisplatin and 5-FU (PF)(3 weekly), P 80mg/m2 d1; d22. 5-Fu 4g/m2 120hciv. d1-5; d22-26; 2. Concurrent chemoradiotherapy with cisplatin and IMRT, P 80mg/m2, d43; d64; 3. Radical radiotherapy: after two periods of induction chemotherapy of PF. PTVnx: 68-70Gy/30-32f PTVnd: 62-68Gy/30-32f PTV1: 60-64Gy/30-32f PTV2: 54-58Gy/30-32f
Sun Yat-sen University Cancer Centre; Sun Yat-sen University Cancer Centre, Hainan Chang'an International Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
 
 
ECOG-ACRIN EA1131, NCT02445391: Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Active, not recruiting
3
415
US, RoW
Capecitabine, Xeloda, Carboplatin, Paraplatin, Carboplatin Novaplus, Cisplatin, Platinol-AQ, Platinol
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
04/21
03/31
TRISS, NCT03214003: Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Completed
3
235
RoW
SIB, chemotherapy with etoposide and cisplatin, Standard
Anhui Shi, MD, Sun Yat-sen University, Fudan University, Xijing Hospital, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Xinjiang Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Air Force General Hospital of the PLA, China-Japan Friendship Hospital, Peking University Third Hospital, Peking Union Medical College Hospital, Beijing Hospital, Beijing Chao Yang Hospital, Peking University People's Hospital, Peking University First Hospital
Small Cell Lung Cancer Limited Stage, Radiotherapy
04/21
01/23
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
ACTRN12615001283561: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)

Active, not recruiting
3
40
 
Australasian Gastro-Intestinal Trials Group, Australasian Gastro-Intestinal Trials Group, Cancer Australia
cholangiocarcinoma, muscle invasive gallbladder carcinoma
 
 
VESPER, NCT01812369: Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer

Active, not recruiting
3
500
Europe
GEMCITABINE CISPLATINE, METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
University Hospital, Rouen
Bladder Cancer
06/21
06/23
TheraCIM1: Stydy of DE-766 in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Recruiting
3
420
Japan
TheraCIM (nimotuzumab)
Daiichi Sankyo
NSCLC
 
 
ChiCTR-IPR-15006378: Comparison the effects of different neoadjuvant chemotherapy regimen on acute toxicity, tumor response, and survival in patients with advanced nasopharyngeal carcinoma

Not yet recruiting
3
108
 
cisplatin and 5-FU chemotherapy once a week ;Traditional PF chemotherapry once three week
Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, the research funds
nasopharyngeal carcinoma
 
 
EHTASEOCCS, NCT03373058: Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery

Recruiting
3
310
RoW
Hyperthermic Intraperitoneal Chemotherapy, HIPEC, cytoreductive surgery, CRS, adjuvant chemotherapy, ACT
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Cancer Hospital of Guizhou Province, Chinese PLA General Hospital, Hebei Medical University Fourth Hospital, The Second Hospital of Hebei Medical University, West China Second University Hospital, Peking Union Medical College Hospital, First Affiliated Hospital, Sun Yat-Sen University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, The Third Affiliated Hospital of Guangzhou Medical University, Wuhan University, RenJi Hospital, Obstetrics & Gynecology Hospital of Fudan University, Southern Medical University, China, Fourth Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Beijing Obstetrics and Gynecology Hospital, Chongqing University Cancer Hospital, Xinqiao Hospital of Chongqing, Wuhan Union Hospital, China, First Affiliated Hospital of Chongqing Medical University, Affiliated Cancer Hospital of Shantou University Medical College
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
07/21
07/23
2019-004630-42: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Not yet recruiting
3
216
Europe
Futibatinib, Cisplatin 1 mg/mL Concentrate for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, TAS-120, Film-coated tablet, Concentrate for solution for infusion, Cisplatin 1 mg/mL Concentrate for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion
Taiho Oncology Inc, Taiho Oncology, Inc., TAIHO ONCOLOGY INC., Taiho Oncology Inc
Advanced solid tumors, Advanced solid tumors, Diseases [C] - Cancer [C04]
 
 
2021-000245-41: Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups. Trattamento con Olaparib oltre la progressione confrontato con chemioterapia a base di platino dopo citoriduzione secondaria in pazienti con recidiva da carcinoma ovarico. MITO 35b, studio di fase 3 randomizzato: un progetto dei Gruppi MITO-MANGO.

Ongoing
3
200
Europe
CARBOPLATINO, LYNPARZA, Cisplatino, Gemcitabina, Paclitaxel, Doxorubicina Liposomiale Pegilata, [CARBOPLATINO], [LYNPARZA], [Cisplatino], [Gemcitabina], [Paclitaxel], [Doxorubicina Liposomiale Pegilata], Concentrate for solution for infusion, Film-coated tablet, LYNPARZA - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE, LYNPARZA - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Diseases [C] - Cancer [C04]
 
 
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Not yet recruiting
3
204
Europe
Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04]
 
 
LEAP-011, NCT03898180 / 2018-003752-21: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ )

Checkmark From LEAP-011 trial in combination with Lenvima for urothelial carcinoma at ESMO 2019
Sep 2019 - Sep 2019: From LEAP-011 trial in combination with Lenvima for urothelial carcinoma at ESMO 2019
Active, not recruiting
3
487
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Urothelial Carcinoma
07/21
07/24
NCT03707509: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
263
RoW
Camrelizumab, SHR-1210, Placebos, Placebo - Concentrate, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplantin Injection
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
08/21
12/22
NCT04490421: Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Recruiting
3
45
RoW
Camrelizumab combined with Apatinib, Etoposide and Cisplatin
Fuzhou General Hospital
Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors
08/21
02/22
CANOPY-1, NCT03631199 / 2018-001547-32: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Hourglass Oct 2021 - Dec 2021 : From CANOPY-1 trial in combination with Keytruda for 1L NSCLC
Checkmark PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Dec 2021 - Dec 2021: PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Checkmark P3 CANOPY-1 trial in combination with canakinumab
Dec 2018 - Dec 2018: P3 CANOPY-1 trial in combination with canakinumab
Active, not recruiting
3
673
Europe, Canada, Japan, US, RoW
canakinumab, ACZ885, canakinumab matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
08/21
06/27
TOPAZ-1, NCT03875235 / 2018-004688-30: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer

Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Jul 2022 - Jul 2022: Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Checkmark From P3 TOPAZ-1 trial for 1L BTC at ASCO-GI 2022
Jan 2022 - Jan 2022: From P3 TOPAZ-1 trial for 1L BTC at ASCO-GI 2022
Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
More
Active, not recruiting
3
810
Europe, Japan, US, RoW
Durvalumab, Placebo
AstraZeneca
Biliary Tract Neoplasms
08/21
03/25
NCT02940925: TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma

Completed
3
241
RoW
Drug: Taxol,cisplatin and capecitabine, Drug: Cisplatin and 5-Fluorouracil
Sun Yat-sen University
Nasopharyngeal Carcinoma
08/21
08/21
NCT03328234: Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

Recruiting
3
2
RoW
SIB-IMRT, Paclitaxel, Platinum-Based Drug, Involved Field Irradiation (IFI)
Chinese Academy of Medical Sciences
IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
08/21
12/22
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
ORIENT-15, NCT03748134: Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( )

Checkmark Data from ORIENT-15 study in advanced or metastatic esophageal squamous cell cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from ORIENT-15 study in advanced or metastatic esophageal squamous cell cancer at ESMO 2021
Completed
3
746
Europe, US, RoW
Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
Innovent Biologics (Suzhou) Co. Ltd., Fortrea
Esophageal Squamous Cell Carcinoma
09/21
07/23
NVALT22, NCT02743923 / 2015-003121-34: Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Active, not recruiting
3
203
Europe
carboplatin, paclitaxel, Bevacizumab, Pemetrexed, cisplatin
The Netherlands Cancer Institute, Dutch Society of Physicians for Pulmonology and Tuberculosis
Carcinoma, Non-Small Cell Lung
09/21
04/24
2021-000830-33: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne La PIPAC (Pressurized intraperitoneal aerosol chemotherapy) nella terapia multimodale per pazienti con metastasi peritoneale limitata da cancro gastrico: studio sperimentale multicentrico randomizzato di fase III. PIPAC_VEROne

Not yet recruiting
3
98
Europe
Oxaliplatino, 5-Fluorouracile, Cisplatino, Doxorubicina, Acido folinico, [Oxaliplatino], [Fluorouracile], [Cisplatino], [Doxorubicina], [Calcio levofolinato], Concentrate for solution for injection/infusion, Solution for injection/infusion, Powder for solution for injection/infusion
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA, Azienda Ospedaliera Universitaria Integrata Verona
Gastric adenocarcinoma with peritoneal metastases Adenocarcinoma gastrico con metastasi peritoneali, Gastric adenocarcinoma with peritoneal metastases Adenocarcinoma gastrico con metastasi peritoneali, Diseases [C] - Digestive System Diseases [C06]
 
 
SIOPEN, NCT01704716: High Risk Neuroblastoma Study 1.8 of SIOP-Europe

Recruiting
3
3300
Europe, RoW
Vincristine, Aldesleukin, Interleukin 2, IL-2, IL2, ch14.18/CHO, anti GD2 antibody, Dinutuximab beta EUSA, Qarziba®, Carboplatin, Paraplatin, Etoposide, VP16, Cisplatin, CDDP, Cyclophosphamide, Endoxan, Doxorubicin, Adriamycin, G-CSF, Filgrastim, Busulfan, Busilvex, Myleran, Busulphan, Melphalan, Alkeran
St. Anna Kinderkrebsforschung
Neuroblastoma
09/21
09/26
NCT03421470: Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer

Recruiting
3
214
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma
10/21
10/21
NCT02974426: To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Terminated
3
132
RoW
PORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Shanghai Chest Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
02/24
02/24
NCT03708042: A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer

Not yet recruiting
3
220
NA
Definitive Radiochemotherapy, Neoadjuvant Radiochemotherapy
Tianjin Medical University Cancer Institute and Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen University, Peking University Cancer Hospital & Institute
Stage II Esophageal Cancer, Stage III Esophageal Cancer
12/21
12/23
JAVELIN Lung 100, NCT02576574 / 2015-001537-24: Avelumab in First-line NSCLC

Checkmark Data from JAVELIN Lung 100 trial for 1L NSCLC
Feb 2022 - Feb 2022: Data from JAVELIN Lung 100 trial for 1L NSCLC
Checkmark Avelumab program rollover study in solid tumor
Jan 2019 - Jan 2019: Avelumab program rollover study in solid tumor
Checkmark Registration study for 1L NSCLC
More
Completed
3
1214
Europe, Canada, Japan, US, RoW
Avelumab, Anti-PD-L1, MSB0010718C, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
First Line Non-Small Cell Lung Cancer
12/21
01/24
UTI-RTOM-NPC, NCT03387774: Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Active, not recruiting
3
176
RoW
Cisplatin, DDP, Intensity Modulated Radiation Therapy, IMRT, Ulinastatin, UTI for injection
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, First People's Hospital of Foshan, People's Hospital of Zhongshan, Fifth Affiliated Hospital, Sun Yat-Sen University
Oral Mucositis (Ulcerative) Due to Radiation
12/21
12/23
NCT01096368: Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Active, not recruiting
3
479
Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Laboratory Biomarker Analysis, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Vincristine, LCR, Leurocristine, VCR, Vincrystine
Children's Oncology Group, National Cancer Institute (NCI)
Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma
12/21
09/24
NCT02621970: Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma

Not yet recruiting
3
534
RoW
Cisplatin 1, DDP, Cisplatin 2, Docetaxel, T, Xeloda, X, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University
Nasopharyngeal Carcinoma
01/22
01/24
R000007398: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial)

Completed
3
230
Japan
gefitinib - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Suita Tokushukai Hospital, AstraZeneca K.K.
Resected pathological stage II or III non-small cell lung cancer with mutated EGFR
 
 
CALLA, NCT03830866 / 2018-002872-42: Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer

Checkmark Presentation of data from CALLA trial for advanced cervical cancer at IGCS 2022
Sep 2022 - Sep 2022: Presentation of data from CALLA trial for advanced cervical cancer at IGCS 2022
Checkmark From CALLA trial for advanced cervical cancer
Mar 2022 - Mar 2022: From CALLA trial for advanced cervical cancer
Completed
3
770
Europe, Japan, US, RoW
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
AstraZeneca
Locally Advanced Cervical Cancer
01/22
07/23
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Germ Cell Tumor
02/22
07/23
RATIONALE 306, NCT03783442 / 2018-000587-28: A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Checkmark Data from RATIONALE 306 trial for 1L locally advanced metastatic esophageal squamous cell carcinoma at ASCO-GI 2023
Dec 2022 - Dec 2022: Data from RATIONALE 306 trial for 1L locally advanced metastatic esophageal squamous cell carcinoma at ASCO-GI 2023
Checkmark Presentation of data from RATIONALE 306 trial for 1L locally advanced metastatic ESCC at ESMO GI 2022
Jun 2022 - Jun 2022: Presentation of data from RATIONALE 306 trial for 1L locally advanced metastatic ESCC at ESMO GI 2022
Checkmark Data from RATIONALE 309 trial for 1L locally advanced, recurrent or metastatic ESCC
More
Active, not recruiting
3
649
Europe, Japan, US, RoW
Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo
BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
02/22
08/24
CALGB-30610, NCT00632853: Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Active, not recruiting
3
731
US, RoW
Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lung Cancer
03/22
 
NCT02460887: The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Active, not recruiting
3
236
RoW
Gemcitabine, cisplatin, DDP, Intensity-modulated Radiotherapy, IMRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
04/22
04/24
NCT04780750: Concurent Chemoradiotherapy in Head and Neck Cancers

Not yet recruiting
3
60
NA
Docetaxel, taxoter
Assiut University
Squamous Cell Carcinoma of Head and Neck
04/22
09/22
2021-003185-12: Pembrolizumab vs Platinum Doublet Chemotherapy in Participants with dMMR Advanced or Recurrent Endometrial Carcinoma in the First-line Setting Pembrolizumab frente a la quimioterapia doble con derivados del platino en participantes con carcinoma endometrial avanzado o recurrente con defectos en la reparación de errores de emparejamiento (dMMR) en primera línea.

Ongoing
3
350
Europe
Solution for infusion, Concentrate for solution for infusion, KEYTRUDA®, Carboplatin Bendalis, Carboplatin Kabi, Cisplatin Teva, Paclitaxel EVER Pharma, Docetaxel EVER Valinject, Docetaxel AqVida, Docetaxel cell pharm, Docetaxel, Cisplatin
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
First-line treatment of participants with dMMR advanced or recurrent EC Estudio de fase 3 de pembrolizumab frente a quimioterapia en el carcinoma endometrial avanzado o recurrente con dMMR., Stage III or IV or recurrent endometrial carcinoma (EC), centrally confirmed as dMMR, with no prior systemic therapy for advanced EC, except radiosensitizing chemotherapy or hormonal therapy. Carcinoma endometrial (CE) en estadio III o IV o recidivante, confirmado con dMMR, sin terapia sistémica previa para el CE avanzado, excepto quimioterapia radiosensibilizante o terapia hormonal., Diseases [C] - Cancer [C04]
 
 
CTONG2003, NCT04768075: Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Not yet recruiting
3
200
NA
Camrelizumab, SHR-1210, Placebo, Simulator of Camrelizumab, Cisplatin, cisplatinum, Carboplatin, Carboplat, Pemetrexed, Pemetrexed disodium, Paclitaxel, Paclitaxel injection, Albumin paclitaxel, Nab-paclitaxel
Guangdong Association of Clinical Trials
Non-Small-Cell Lung Cancer
04/22
04/24
NCT04414566: Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruiting
3
562
RoW
gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil, GP;TPF, IMRT, IMRT and concurrent cisplatin
West China Hospital
Nasopharyngeal Carcinoma
05/22
05/25
KEYNOTE-412, NCT03040999 / 2016-003934-25: Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/)

Checkmark Presentation of data from KEYNOTE-412 trial for locally advanced SCCHN at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-412 trial for locally advanced SCCHN at ESMO 2022
Checkmark Results from KEYNOTE-412 trial for unresected locally advanced HNSCC
Jul 2022 - Jul 2022: Results from KEYNOTE-412 trial for unresected locally advanced HNSCC
Active, not recruiting
3
804
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, Placebo, Cisplatin, Platinol®, Platinol®-AQ, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy
Merck Sharp & Dohme LLC
Head and Neck Neoplasms
05/22
08/24
NACA, NCT02607592: A Prospective Multi-center Phase III Randomized Controlled Trial

Recruiting
3
293
RoW
cisplatin and pemetrexed, nedaplatin+pemetrexed
Sun Yat-sen University
Carcinoma，Non-Small-Cell Lung
06/22
12/22
NCT01951469: Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Recruiting
3
160
RoW
Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy
Sun Yat-sen University, Wu Jieping Medical Foundation
Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation
06/22
12/22
NCT03955367: Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Recruiting
3
638
RoW
Prophylactic extended-field Irradiation, Prophylactic radiotherapy for para-aortic lymph nodes region, Pelvic irradiation, Pelvic radiotherapy, Intracavitary brachytherapy, Brachytherapy, Concurrent chemotherapy, Chemotherapy
Peking Union Medical College Hospital, Peking University First Hospital, Cangzhou Central Hospital, The Second Affiliated Hospital of Dalian Medical University, Tumor Hospital of Gansu, First Affiliated Hospital of Guangxi Medical University, Harbin Medical University Third Affiliated Hospital, Wuhan Union Hospital, China, First Affiliated Hospital of Chongqing Medical University, Guizhou Provincial People's Hospital, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Jilin Provincial Tumor Hospital, Jiangsu Cancer Institute & Hospital, The 940th Hospital of Joint Logistics Support Force，PLA., General Hospital of Benxi Iron & Steel Industry Group, The Affiliated Hospital of Inner Mongolia Medical University, General Hospital of Ningxia Medical University, Beijing Obstetrics and Gynecology Hospital, Tangshan People's Hospital, Zhongnan Hospital of Wuhan University & Second Clinical Hospital of Wuhan University, Second Affiliated Hospital of Xi'an Jiaotong University, First Affiliated Hospital Xi'an Jiaotong University, The Affiliated Tumor Hospital of Xinjiang Medical University, Zhejiang Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, Affiliated Cancer Hospital of Zhengzhou University, Seventh Medical Center of PLA Army General Hospital, Shengjing Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Xiangya Hospital of Central South University, Henan Provincial People's Hospital, Xi'an Gaoxin Hospital, West China Second University Hospital, The Forth Affiliated Hospital of Guangxi Medical University
Uterine Cervical Neoplasms
06/22
06/25
ChiCTR-IIR-17012529: A prospective randomized controlled clinical trial of docetaxel plus cisplatin induction chemotherapy 2 or 3 cycle followed by concurrent chemoradiotherapy in the treatment of locally localized advanced nasopharyngeal carcinoma

Recruiting
3
200
 
docetaxel plus cisplatin induction chemotherapy 2 cycle followed by concurrent chemoradiotherapy ;docetaxel plus cisplatin induction chemotherapy 3 cycle followed by concurrent chemoradiotherapy
Xiangya Hospital of Central South University; Xiangya Hospital of Central South University, Xiangya Medical Research Funding
Nasopharyngeal carcinoma
 
 
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Active, not recruiting
3
320
RoW
Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
06/22
12/23
NCT04914598: A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Not yet recruiting
3
290
RoW
ENDOSTAR，cisplatin, Placebo , cisplatin
Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Pleural Effusion
06/22
10/23
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico

Not yet recruiting
3
324
Europe
Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
2020-005452-38: Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin

Not yet recruiting
3
830
Europe
Durvalumab, Tremelimumab, Enfortumab vedotin, MEDI4736, EV, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI, Padcev
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Documented muscle-invasive urothelial carcinoma (UC) of the bladder incisplatin ineligible patients or Who Refuse Cisplatin, Cancer in thick muscle in the bladder wall, Diseases [C] - Cancer [C04]
 
 
SUMC-EC-002, NCT02556762: Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer

Active, not recruiting
3
202
RoW
Radiotherapy with simultaneous modulated accelerated boost, SIB, Standard dose radiotherapy, PF
Chuangzhen Chen
Esophageal Cancer
03/22
12/24
2021-005879-40: Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Estudio en fase III de patritumab deruxtecán frente a quimioterapia basada en platino en el CPNM metastásico o localmente avanzado con EGFRm tras el fracaso del tratamiento con ITC del EGFR

Not yet recruiting
3
560
Europe
Patritumab Deruxtecan, Pemetrexed, Cisplatin, Carboplatin, U3-1402, NA, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Vitamin B12 1000 µg, Folic Acid, Cisplatin, carboplatin, pemetrexed
Daiichi Sankyo, Inc., DAIICHI SANKYO INC., DAIICHI SANKYO. INC., Daiichi Sankyo, Inc.
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm), Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM), Diseases [C] - Cancer [C04]
 
 
MC1675, NCT02908477: Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

Active, not recruiting
3
228
US
Adjuvant Radiation Therapy, Docetaxel, Taxotere, Cisplatin, cisplatinum
Mayo Clinic
Oropharynx Cancer
08/22
09/24
IMvigor130, NCT02807636 / 2016-000250-35: Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Checkmark From IMvigor130 trial in 1L urothelial cancer
Sep 2019 - Sep 2019: From IMvigor130 trial in 1L urothelial cancer
Completed
3
1213
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Carboplatin, Gemcitabine, Placebo, Cisplatin
Hoffmann-La Roche
Urothelial Carcinoma
08/22
02/24
NCT03201861: Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

Recruiting
3
762
RoW
Paclitaxel, Cisplatin, Taxol, EC to docetaxel or paclitaxel
RenJi Hospital
Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast
08/22
12/22
CRTCOESC, NCT02025036: Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer

Active, not recruiting
3
249
RoW
Capecitabine(Aibin), Aibin, Oxaliplatin(Aiheng), Aiheng, Radiotherapy, Radiation Therapy
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang Central Hospital, Military 150 Hospital, Anyang Cancer Hospital, Nanyang Central Hospital, Henan Oncology Hospital, The First Affiliated Hospital of Xinyang Medical College, Sanmenxia Central Hospital
Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma
09/22
04/25
ChiCTR2000035449: A study for comparing efficacy and safety of lobaplatin versus cisplatin concurrent chemoradiotherapy for cervical cancer

Not yet recruiting
3
112
 
lobaplatin ;cisplatin
Shanghai Jiao Tong University Affliated Sixth People's Hospital; Shanghai Jiao Tong University Affliated Sixth People's Hospital, Shanghai Shenkang Development Center
Cervical cancer
 
 
KEYNOTE-826, NCT03635567 / 2018-001440-53: Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/)

Checkmark Full data from KEYNOTE-826 study for Keytruda + chemotherapy with/without bevacizumab for recurrent/metastatic 1L cervical cancer at ESMO 2021
Sep 2021 - Sep 2021: Full data from KEYNOTE-826 study for Keytruda + chemotherapy with/without bevacizumab for recurrent/metastatic 1L cervical cancer at ESMO 2021
Checkmark From KEYNOTE-826 trial in combination with Avastin and chemotherapy for 1L cervical cancer
Jun 2021 - Jun 2021: From KEYNOTE-826 trial in combination with Avastin and chemotherapy for 1L cervical cancer
Completed
3
617
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Cisplatin, PLATINOL®, Carboplatin, PARAPLATIN®, Bevacizumab, AVASTIN®, Placebo to pembrolizumab, Normal Saline or Dextrose solution
Merck Sharp & Dohme LLC
Cervical Cancer
10/22
06/24
KEYNOTE-859, NCT03675737 / 2018-001757-27: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/)

Checkmark Topline data from KEYNOTE-859 trial for HER2- 1L advanced gastric or gastroesophageal junction adenocarcinoma
Nov 2022 - Nov 2022: Topline data from KEYNOTE-859 trial for HER2- 1L advanced gastric or gastroesophageal junction adenocarcinoma
Active, not recruiting
3
1579
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, PLATINOL®, 5-fluorouracil, ADRUCIL®, 5FU, oxaliplatin, ELOXATIN®, capecitabine, XELODA®, Placebo for Pembrolizumab
Merck Sharp & Dohme LLC
Stomach Neoplasms
10/22
03/25
PEARL, NCT03003962 / 2018-001375-21: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer

Checkmark Data from PEARL trial for Stage IV (metastatic) NSCLC
Dec 2022 - Dec 2022: Data from PEARL trial for Stage IV (metastatic) NSCLC
Checkmark From PEARL trial for 1L NSCLC
Oct 2021 - Oct 2021: From PEARL trial for 1L NSCLC
Active, not recruiting
3
669
Europe, US, RoW
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
10/22
06/26
NCT02610010: Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma

Recruiting
3
462
RoW
Cisplatin, DDP, Intensity-modulated radiotherapy
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University
Nasopharyngeal Carcinoma
11/22
11/25
2022-001144-18: A clinical study comparing efficacy and safety of xevinapant against placebo when given with radiotherapy in participants who had their locally advanced squamous cell carcinoma of the head and neck removed by surgery, are at high risk for the cancer to return and who cannot be treated with high-dose cisplatin.

Ongoing
3
700
RoW
Xevinapant, MSC2735845A, Oral solution
Merck Healthcare KGaA, Merck Healthcare KGaA
Resected squamous cell carcinoma of the head and neck, Resected squamous cell carcinoma of the head and neck, Diseases [C] - Cancer [C04]
 
 
AEGEAN, NCT03800134 / 2018-002997-29: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Event free survival data from AEGEAN trial for stage I and III resected NSCLC
Jan 2023 - Dec 2023: Regulatory submission for locally advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for advanced stage 3 NSCLC (based on AEGEAN trial)
Jan 2023 - Dec 2023: From AEGEAN trial for stage II and III resected NSCLC
More
Active, not recruiting
3
826
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
AstraZeneca
Non-Small Cell Lung Cancer
11/22
09/28
HIPOVA-01, NCT03220932 / 2019-002480-94: Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

Not yet recruiting
3
132
Europe
Cytoreductive surgery combined with HIPEC, Chemotherapy and bevacizumab (CT-BEV)
Hospices Civils de Lyon
Ovarian Epithelial Cancer
11/22
11/22
SYSGO-003, NCT02629718: Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer

Recruiting
3
700
RoW
NACT (Paclitaxel + Cisplatin or carboplatin), radical surgery
Sun Yat-sen University
PFS, OS, Quality of Life
12/22
12/22
IRCNPC, NCT03015727: Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma

Recruiting
3
440
RoW
Docetaxel, DOC, Cisplatin, DDP, IMRT/TOMO, Chemotherapy, concurrent chemotherapy
Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, The Central Hospital of Lishui City, Jinhua Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Eastern Hospital, People's Hospital of Quzhou
Locally Advanced Nasopharyngeal Carcinoma
12/22
12/24
NCT02973386: Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Active, not recruiting
3
278
RoW
IMRT combine with cisplatin concurrent chemotherapy, IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Sun Yat-sen University
Local Advanced High Risk Nasopharyngeal Carcinoma
10/22
12/25
NCT03381066: A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Recruiting
3
225
RoW
gefitinib, pemetrexed,cisplatin, Intercalating arm, Vinorelbine, cisplatin, chemotherapy alone arm
Yonsei University
Completely Resected NSCLC With Common EGFR Mutations
12/22
12/22
NCT04426955: Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Active, not recruiting
3
396
RoW
Camrelizumab, SHR-1210, Paclitaxel, Cisplatin, Placebo, Radiation
Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer
12/22
12/23
KEYNOTE-966, NCT04003636: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/)

Checkmark Interim results from KEYNOTE-966 trial in combination chemotherapy for patients with advanced or unresectable 1L BTC.
Jan 2023 - Jan 2023: Interim results from KEYNOTE-966 trial in combination chemotherapy for patients with advanced or unresectable 1L BTC.
Active, not recruiting
3
1069
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Gemcitabine, Gemzar, Cisplatin, Platinol®, Platinol®-AQ, Placebo
Merck Sharp & Dohme LLC
Biliary Tract Carcinoma
12/22
11/24
KEYNOTE-966 China Extension study, NCT04924062: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Active, not recruiting
3
158
RoW
Pembrolizumab, MK-3475, Gemcitabine, Gemzar, Cisplatin, Platinol®, Platinol®-AQ, Placebo
Merck Sharp & Dohme LLC
Biliary Tract Carcinoma
12/22
11/24
 

Download Options